Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Sun, JD; Liu, Q; Wang, J; Ahluwalia, D; Ferraro, D; Wang, Y; Duan, JX; Ammons, WS; Curd, JG; Matteucci, MD; Hart, CP

dc.contributor.author	Sun, JD	en
dc.contributor.author	Liu, Q	en
dc.contributor.author	Wang, J	en
dc.contributor.author	Ahluwalia, D	en
dc.contributor.author	Ferraro, D	en
dc.contributor.author	Wang, Y	en
dc.contributor.author	Duan, JX	en
dc.contributor.author	Ammons, WS	en
dc.contributor.author	Curd, JG	en
dc.contributor.author	Matteucci, MD	en
dc.contributor.author	Hart, CP	en
dc.coverage.spatial	United States	en
dc.date.accessioned	2012-06-12T23:19:13Z	en
dc.date.available	2012-06-12T23:19:13Z	en
dc.date.issued	2012	en
dc.identifier.citation	Clin Cancer Res 18(3):758-770 01 Feb 2012	en
dc.identifier.issn	1078-0432	en
dc.identifier.other	1078-0432.CCR-11-1980	en
dc.identifier.uri	http://hdl.handle.net/2292/18965	en
dc.description.abstract	Tumor hypoxia underlies treatment failure and yields a more aggressive, invasive, and metastatic cancer phenotype. TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM). The purpose of this study is to characterize the antitumor activity of TH-302 and investigate its selective targeting of the hypoxic cells in human tumor xenograft models.	en
dc.language	eng	en
dc.publisher	American Association for Cancer Research	en
dc.relation.ispartofseries	Clinical Cancer Research	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.source.uri	http://dx.doi.org/10.1158/1078-0432.CCR-11-1980	en
dc.subject	Animals	en
dc.subject	Antineoplastic Agents	en
dc.subject	Cell Hypoxia	en
dc.subject	Cell Line, Tumor	en
dc.subject	Female	en
dc.subject	Humans	en
dc.subject	Immunohistochemistry	en
dc.subject	Mice	en
dc.subject	Mice, SCID	en
dc.subject	Neoplasms, Experimental	en
dc.subject	Neovascularization, Pathologic	en
dc.subject	Nitroimidazoles	en
dc.subject	Phosphoramide Mustards	en
dc.subject	Prodrugs	en
dc.subject	Xenograft Model Antitumor Assays	en
dc.title	Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.	en
dc.type	Journal Article	en
dc.identifier.doi	10.1158/1078-0432.CCR-11-1980	en
pubs.issue	3	en
pubs.begin-page	758	en
pubs.volume	18	en
dc.rights.holder	Copyright: American Association for Cancer Research	en
pubs.declined	2016-08-17T16:18:01.493+1200	en
pubs.declined	2016-08-18T19:27:35.419+1200	en
pubs.declined	2016-08-19T16:07:01.640+1200	en
pubs.declined	2016-08-21T20:43:37.824+1200	en
pubs.declined	2016-08-22T16:11:54.88+1200	en
pubs.declined	2016-08-23T16:11:12.277+1200	en
pubs.declined	2016-08-24T17:07:51.429+1200	en
pubs.declined	2016-08-25T16:09:23.836+1200	en
pubs.declined	2016-08-26T16:42:21.93+1200	en
pubs.declined	2016-08-27T16:36:06.949+1200	en
pubs.declined	2016-08-28T16:41:20.827+1200	en
pubs.declined	2016-08-29T16:13:07.830+1200	en
pubs.declined	2016-08-30T16:07:43.848+1200	en
pubs.declined	2016-08-31T16:09:01.611+1200	en
pubs.declined	2016-09-01T16:19:59.732+1200	en
pubs.declined	2016-09-02T16:20:51.715+1200	en
pubs.declined	2016-09-03T17:23:46.991+1200	en
pubs.declined	2016-09-04T18:17:42.43+1200	en
pubs.declined	2016-09-05T18:41:25.196+1200	en
pubs.declined	2016-09-06T20:58:01.958+1200	en
pubs.declined	2016-09-15T17:03:20.906+1200	en
pubs.declined	2016-10-26T17:29:41.872+1300	en
pubs.declined	2016-10-27T17:06:50.557+1300	en
pubs.declined	2016-11-25T17:05:30.650+1300	en
pubs.declined	2016-12-05T18:29:20.474+1300	en
pubs.declined	2016-12-06T18:54:51.792+1300	en
pubs.declined	2016-12-08T17:03:54.473+1300	en
pubs.declined	2016-12-17T18:36:00.449+1300	en
pubs.declined	2016-12-20T17:15:58.128+1300	en
pubs.declined	2017-01-29T17:00:24.560+1300	en
pubs.declined	2017-03-05T17:31:55.711+1300	en
pubs.declined	2017-03-20T09:00:24.377+1300	en
pubs.declined	2017-04-02T17:34:20.141+1200	en
pubs.declined	2017-04-16T17:32:36.695+1200	en
pubs.declined	2017-04-30T17:21:43.677+1200	en
pubs.declined	2017-05-14T17:05:41.572+1200	en
pubs.declined	2017-06-05T07:17:56.989+1200	en
pubs.declined	2017-06-11T17:04:56.524+1200	en
pubs.declined	2017-06-25T17:03:36.859+1200	en
pubs.declined	2017-07-09T17:05:37.470+1200	en
pubs.declined	2017-09-03T18:45:43.429+1200	en
pubs.declined	2017-09-17T17:08:08.327+1200	en
pubs.declined	2017-10-01T17:40:57.227+1300	en
pubs.declined	2017-10-15T17:41:06.83+1300	en
pubs.declined	2017-11-12T17:42:05.526+1300	en
pubs.declined	2017-11-26T17:02:43.599+1300	en
pubs.declined	2017-12-10T17:27:05.686+1300	en
pubs.declined	2017-12-24T17:09:20.924+1300	en
pubs.declined	2018-01-07T17:38:51.474+1300	en
pubs.declined	2018-01-21T17:24:43.755+1300	en
pubs.declined	2018-02-25T17:44:47.38+1300	en
pubs.declined	2018-03-04T17:43:48.797+1300	en
pubs.declined	2018-03-11T17:29:19.108+1300	en
pubs.declined	2018-03-18T17:41:07.737+1300	en
pubs.declined	2018-04-08T17:19:38.648+1200	en
pubs.declined	2018-04-15T17:38:06.553+1200	en
pubs.declined	2018-05-27T17:04:38.362+1200	en
pubs.declined	2018-06-03T17:15:28.614+1200	en
pubs.declined	2018-06-17T17:21:11.419+1200	en
pubs.declined	2018-06-24T17:40:14.361+1200	en
pubs.declined	2018-07-08T17:11:54.167+1200	en
pubs.declined	2018-07-15T17:18:29.155+1200	en
pubs.declined	2018-07-29T17:20:12.36+1200	en
pubs.declined	2018-08-19T17:09:17.568+1200	en
pubs.declined	2018-08-26T17:27:40.72+1200	en
pubs.declined	2018-09-02T17:05:49.625+1200	en
pubs.declined	2018-09-16T17:37:21.480+1200	en
pubs.declined	2018-09-23T17:17:43.875+1200	en
pubs.declined	2018-10-14T18:10:12.920+1300	en
pubs.declined	2018-10-28T17:05:58.493+1300	en
pubs.declined	2018-11-25T17:17:32.706+1300	en
pubs.declined	2018-12-16T17:31:34.355+1300	en
pubs.declined	2018-12-23T18:12:59.555+1300	en
pubs.declined	2018-12-31T09:04:22.741+1300	en
pubs.declined	2019-01-13T17:43:28.25+1300	en
pubs.declined	2019-01-20T17:06:30.865+1300	en
pubs.declined	2019-01-27T17:23:25.684+1300	en
pubs.declined	2019-02-17T17:05:01.503+1300	en
pubs.declined	2019-03-10T17:23:09.290+1300	en
pubs.declined	2019-03-31T17:07:05.535+1300	en
pubs.declined	2019-04-28T17:05:25.883+1200	en
pubs.declined	2019-06-23T17:06:08.701+1200	en
pubs.declined	2019-07-21T17:06:57.134+1200	en
pubs.declined	2019-09-01T17:06:34.266+1200	en
pubs.declined	2019-09-08T18:27:06.953+1200	en
pubs.declined	2019-09-15T17:06:59.324+1200	en
pubs.declined	2019-09-29T17:06:26.450+1300	en
pubs.declined	2019-10-06T17:28:11.671+1300	en
pubs.declined	2020-01-05T17:04:23.28+1300	en
pubs.declined	2020-02-09T17:24:49.173+1300	en
pubs.declined	2020-04-26T17:06:22.897+1200	en
pubs.declined	2020-05-24T17:05:53.486+1200	en
pubs.declined	2020-06-21T17:11:37.710+1200	en
pubs.declined	2020-07-05T17:11:02.884+1200	en
pubs.declined	2020-07-26T17:56:06.355+1200	en
pubs.declined	2020-08-16T17:09:45.712+1200	en
pubs.declined	2020-08-23T17:33:00.465+1200	en
pubs.end-page	770	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.elements-id	300023	en